BGI Genomics(SZ:300676) Xin Lang Cai Jing·2026-01-19 01:39Core Viewpoint - On January 16, BGI Genomics experienced a decline of 6.85% in stock price, with a trading volume of 1.168 billion yuan, indicating significant market activity and investor sentiment concerns [1]. Financing and Trading Activity - On January 16, BGI Genomics had a financing buy-in amount of 107 million yuan and a financing repayment of 242 million yuan, resulting in a net financing outflow of 136 million yuan [1]. - As of January 16, the total financing and securities lending balance for BGI Genomics was 1.131 billion yuan, with the financing balance of 1.127 billion yuan accounting for 5.09% of the circulating market value, which is above the 90th percentile of the past year [1]. - The company repaid 33,700 shares in securities lending on January 16, with a sell amount of 17,490 yuan, while the remaining securities lending volume was 60,500 shares, with a balance of 3.2065 million yuan, indicating a low position compared to the 30th percentile of the past year [1]. Company Overview - BGI Genomics, established on July 9, 2010, and listed on July 14, 2017, is located in Shenzhen, Guangdong Province, and specializes in providing research services and precision medical testing solutions through multi-omics big data technologies [2]. - The company's main business revenue composition includes: 42.67% from precision medical testing solutions, 26.12% from reproductive health research and clinical application services, 17.08% from multi-omics big data services, 11.00% from tumor and chronic disease prevention and translational medicine services, 2.36% from infection prevention research and clinical application services, and 0.78% from other services [2]. - As of September 30, 2025, BGI Genomics had 67,900 shareholders, an increase of 5.58% from the previous period, with an average of 6,127 circulating shares per person, a decrease of 5.28% [2]. Financial Performance - For the period from January to September 2025, BGI Genomics reported a revenue of 2.674 billion yuan, a year-on-year decrease of 5.39%, while the net profit attributable to the parent company was -21.387 million yuan, reflecting an increase of 82.78% year-on-year [2]. Dividend Distribution - Since its A-share listing, BGI Genomics has distributed a total of 1.024 billion yuan in dividends, with 455 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders of BGI Genomics, Huabao Zhongzheng Medical ETF ranked third with 7.1098 million shares, a decrease of 1.2088 million shares from the previous period [3]. - E Fund's Growth Enterprise Board ETF ranked fourth with 5.2957 million shares, down by 816,600 shares, while Southern Zhongzheng 500 ETF ranked sixth with 3.7411 million shares, an increase of 13,700 shares [3]. - Hong Kong Central Clearing Limited ranked seventh with 2.6059 million shares, an increase of 26,200 shares, while the招商优势企业混合A fund exited the top ten circulating shareholders list [3].